Pharmaceutical composition comprising daunorubicin potentiated w

Details Pharmaceutical composition comprising daunorubicin potentiated w Pharmaceutical composition comprising daunorubicin potentiated w

1991-07-26

1993-01-26

Nutter, Nathan M.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

514183, 514185, 514283, 514400, A01N 4304, A01N 4342, A61K 3133, A61K 3170

Patent

active

051822687

ABSTRACT:
2,4,5-Tri(4-methoxyphenyl)-4,5-dihydroimidazole, or a pharmaceutically acceptable salt thereof, is employed as a cancer drug potentiator or as an antimetastis drug.

REFERENCES:
Zimmerman et al., Proc. Annu. Meeting of the Am. Cancer Society 25: p. 351 (1984)-Abstract 1393.
Zupanc, et al. Glasmk Hemicara I Technologa BiH. Sarajevo 27/28 (1980-1981) Bull Soc. Chem. and Technolog, Sarajevo, p. 71-80.
Williams et al., Jacs 1959, 21(3): 4464-4469.
Honn et al., Biochem Pharm. 34: pp. 235-241 (1985), "Ihibition by Dithydropyridine Class Calcium Channel Blockers of Tumor Cell-Platelet-Endothelial Cell Inter Actions in Vitro and, in Vivo Metatases."
Tsuruo et al., Cancer Chemother. Pharmacol. 14: pp. 30-33 (1985), "Inhibition of Spontaneous and Experimental Tumor Mestasis by the Calcium Antogonist Nerapamil".
Onoda et al., Cancer Lett. 30: pp. 181-188 (1986), "Cisplatin with Nifidipine: Synergistic Cytoxicity Against Murine Solid Tumors and Their Metatases".
Onoda et al., Proc. Annu. Meet. Am. Assoc. Cancer Res. 25: p. 351 (1984), "Antimetastic Effect of the Calcium Channel Blocker Diltiazem".
Honn et al., Proc. Soc. Exp. Biol. Med. 174: pp. 16-19 (1983), "Calcium Channel Blockers: Potential Antimetastatic Agents".
Honn et al., Treatment of Metastasis: Problems and Prospects, pp. 259-262 (1984) "Antimetastatic Therapy with Calcium Active Compounds".
Pauwels-Veraghy et al., Fourth European Conference on Clinical Oncology and Cancer Nursing, Madrid, Nov. 1-4, 1987 Federation of European Cancer Societies, 1987, p. 88.
Bessho et al., Medical and Pediatric Oncology, 13: pp. 199-202 (1985), Treatment of Children with Refractory Acute Lymphotic Leukemia with Vincristine and Diltiazem.
Ahmed et al., Eur. J. Cancer Clin. Oncol., 23: pp. 1329-1336 (1987), "Characterization of Daunorubin Resistance in K562 Leukemia Cells Lacking Daunorubin Reductase Activity".
Helson, Cancer Drug Delivery, 1: pp. 353-361 (1984), "Calcium Channel Blocker Enhancement of Anticancer Drug Cytoricity"-A Review.
Tsurno et al., Cancer Research, 43: pp. 2905-2910 (1983), "Circumvention of Vincristine and Andriamycin Resistance in Vitro and in Vivo by Calcium Influx Blockers".

Affiliated with

Also associated with

Rating

Pharmaceutical composition comprising daunorubicin potentiated w does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical composition comprising daunorubicin potentiated w, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical composition comprising daunorubicin potentiated w will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1412720